The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with
Epizyme has scored an important FDA win after the regulator approved its Tazverik (tazemetostat) in follicular lymphoma. Tazverik is already approved in
NICE has recommended NHS funding for Roche’s Rozlytrek (entrectinib) as a treatment option for advanced non-small cell lung cancer with a rare mutation in
